In The Field - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

In The Field

Pharmaceutical Technology

The International Federation of Pharmaceutical Manufacturers & Associations (Geneva, Switzerland, is collaborating with WHO to help developing countries gain access to pandemic influenza vaccines through technology transfer, and Sanofi-Aventis (Paris, France, http:// ) already has transferred vaccine technology to the Brazilian government. The government passed the technology on to the Butantã Institute (Sao Paulo, Brazil,, which has begun producing vaccines. In addition, WHO is working with UNICEF to help developing countries find financing to access products manufactured by multinational vaccine producers.

Influenza vaccine production could be made easier if cell culture-derived vaccines become more prevalent. Novartis's "Optaflu" influenza vaccine recently was recommended for approval by the Committee for Medicinal Products for Human Use. Optaflu could be the first influenza vaccine to reach the market that uses a mammalian cell line rather than chicken eggs for antigen production. According to Dr. Jorg Reinhardt, chief executive officer of Novartis Vaccines and Diagnostics, cell culture-derived vaccines can be scaled up quickly and easily in the event of a pandemic. Virus cultivation also could be more robust because most circulating viral strains are unable to replicate in chicken eggs.
-Brianne Harrison


FDA Licenses Sanofi-Pasteur's H5N1 Vaccine

Lyon, France (Apr. 17)—Sanofi-Pasteur (http://, the vaccine division of the Sanofi-Aventis Group, announced that the US Food and Drug Administration (Rockville, MD, has licensed its H5N1 vaccine, making it the first avian-influenza vaccine for humans in the US. The vaccine will be part of the government's vaccine-stockpile program to prepare for a potential pandemic.

Company Notes
Licensure was based on a clinical trial conducted by the National Institute of Allergy and Infectious Diseases completed in 2005.

Although no human cases of H5N1 infection have been reported in the US, nearly 300 people worldwide have been infected with the virus since 2003, and more than half have died.

Ensuring sufficient manufacturing capacity to provide an adequate number of doses remains a challenge, however, as worldwide agencies develop strategies for timely development, manufacture, and distribution.

"We are working closely with other government agencies, global partners, and the vaccine industry to facilitate development, licensure, and availability of needed supplies of safe and effective vaccines to protect against the pandemic threat," said Jesse Goodman, MD, MPH, director of FDA's Center for Biologics Research and Evaluation, in an FDA release.
-Maribel Rios


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Source: Pharmaceutical Technology,
Click here